TNFSF11 and breast carcinoma: To determine osteoclast formation, RAW 264.7 pre-osteoclasts were tri-cultured with breast cancer cells plus EO cells (Figure 4c) or plus naïve osteoblasts (control; Figure 4b) in the presence of exogenous RANKL for six days.